Biotech startups in Cambridge, Massachusetts
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Insilico Medicine | Cambridge | Series E | $123.0M | 2025-03-13 |
| ConcertAI | Cambridge | Series C | $150.0M | 2022-03-29 |
| Biobot Analytics | Cambridge | Series A | $13.4M | 2025-06-06 |
| Dyno Therapeutics | Cambridge | Series A | $100.0M | 2021-05-06 |
| Inari | Cambridge | Series G | $144.0M | 2025-01-07 |
| Cognito Therapeutics | Cambridge | Series C | $105.0M | 2026-03-05 |
| Terrestrial Bio | Cambridge | Series C | $50.0M | 2026-03-26 |
| Simnova | Cambridge | Series B | $59.3M | 2026-08-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 272 biotech startups in Cambridge, Massachusetts have raised $19.8B in total.
- 38 of them closed their most recent round in the last 12 months, $1.5B combined.
- The largest of those rounds is LifeMine Therapeutics' $188.0M Series E, dated August 2026.
- The most recent is Sanyou Bio's $15.0M Series C on 9 November 2026.
- F-Prime is an investor in 6 of them, more than any other fund.
- Health care is the most common other sector, with 243 companies (89%).
- 36% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (49% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
25 of 272| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Simnova | Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. | Biotech | Series B | $59.3M | 2026-08-18 | $87.2M | Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 | 51 to 100 | 2019 |
| Elemental Machines | Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. | Artificial intelligence | Series B | $5.7M | 2026-05-27 | $66.5M | Founders Fund, Tau Ventures, Rock Health Capital +2 | 11 to 50 | 2015 |
| Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
| Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| Atavistik Bio | Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. | Biotech | Series B | $40.0M | 2026-03-05 | $260.0M | Lux Capital, The Column Group, Nextech Invest | 11 to 50 | 2021 |
| Stata DX | Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. | Biotech | Series A | $400K | 2026-02-27 | $3.6M | MassVentures | 1 to 10 | 2022 |
| Nocion Therapeutics | Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. | Biotech | Series B | $23.0M | 2026-01-07 | $134.0M | Canaan Partners, F-Prime, OUP (Osage University Partners) +2 | 11 to 50 | 2017 |
| Prudentia Sciences | Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. | Artificial intelligence | Series A | $20.0M | 2026-01-07 | $27.0M | Google Ventures, Iaso Ventures, Virtue | 1 to 10 | 2023 |
| STRM.BIO | STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy. | Biotech | Seed | $8.0M | 2026-01-07 | $10.1M | Bill & Melinda Gates Foundation, NYBC Ventures, NCATS | 11 to 50 | 2019 |
| NeuroBionics | NeuroBionics develops bioelectronic medicine devices that treat disease by modulating nerve activity. | Biotech | Seed | $4.2M | 2025-12-10 | $9.2M | MedTech Innovator, Dolby Family Ventures, GreyMatter +1 | 1 to 10 | 2023 |
| Kano Therapeutics | Kano Therapeutics develops single-stranded DNA for targeted gene correction. | Biotech | Seed | $5.0M | 2025-11-07 | $7.1M | Metaplanet, Taihill Venture, Vsquared Ventures +2 | 1 to 10 | 2021 |
| Biobot Analytics | Biobot Analytics offers a wastewater data platform that delivers population-level health insights. | Artificial intelligence | Series A | $13.4M | 2025-06-06 | $41.4M | Y Combinator, Pioneer Fund, Soma Capital +2 | 11 to 50 | 2017 |
| AIRNA | AIRNA develops RNA editing technologies to create medicines for various diseases. | Biotech | Series B | $155.0M | 2025-04-01 | $245.0M | ARCH Venture Partners, Alexandria Venture Investments, Forbion Capital Partners +2 | 51 to 100 | 2021 |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development targeting cancer and age-related diseases. | Artificial intelligence | Series E | $123.0M | 2025-03-13 | $624.3M | Qiming Venture Partners, F-Prime, Warburg Pincus +1 | 101 to 250 | 2014 |
| Inari Unicorn | Inari is a seed design and biotechnology company developing seeds for a nature-positive food system. | Biotech | Series G | $144.0M | 2025-01-07 | $753.0M | EDBI, Alexandria Venture Investments, CPP Investments +2 | 251 to 500 | 2016 |
| Nabla Bio | Nabla Bio uses an autoverse platform of biologically informed machine learning to co-develop antibody drugs. | Artificial intelligence | Series A | $26.0M | 2024-05-14 | $37.4M | Y Combinator, Khosla Ventures, National Science Foundation +2 | 11 to 50 | 2020 |
| NextPoint Therapeutics | NextPoint Therapeutics develops therapeutics to treat cancer patients as a clinical-stage biotechnology company. | Biotech | Series B | $42.5M | 2024-02-14 | $122.5M | Invus, Leaps by Bayer, Catalio Capital Management +2 | 51 to 100 | 2020 |
| Elemind Technologies | Elemind Technologies develops neuromodulation techniques that shape brainwaves and change brain states. | Biotech | Seed | $12.0M | 2024-02-06 | $12.0M | Village Global, E14 Fund, Evolution VC Partners +2 | 11 to 50 | 2019 |
| Nvelop Therapeutics | Nvelop Therapeutics develops genetic medicines for patients with severe genetic diseases. | Biotech | Seed | $100.0M | 2023-09-20 | $100.0M | F-Prime, Atlas Venture, 5AM Ventures +1 | 51 to 100 | 2022 |
| ROME Therapeutics | ROME Therapeutics develops therapies for cancer and autoimmune diseases by targeting the repeatome. | Biotech | Series B | $72.0M | 2023-09-12 | $199.0M | Andreessen Horowitz, Google Ventures, Alexandria Venture Investments +2 | 11 to 50 | 2020 |
| Luminopia | Luminopia develops digital treatments for significant neuro-visual disorders. | Biotech | Series A | $16.0M | 2023-06-27 | $33.1M | MassChallenge, U.S. Venture Partners, Bantam Group +2 | 11 to 50 | 2015 |
| InsideTracker | InsideTracker provides a platform that analyzes and tracks key biochemical and physiological markers. | Biotech | Series B | $15.0M | 2022-09-06 | $18.2M | OurCrowd, MassVentures, Puget Sound Venture Club +2 | 11 to 50 | 2009 |
| ConcertAI Unicorn | ConcertAI sells AI-powered SaaS data tools for medical research in oncology. | Artificial intelligence | Series C | $150.0M | 2022-03-29 | $300.0M | Maverick Ventures, Sixth Street, Declaration Partners +2 | 1,001 to 5,000 | 2018 |
| Dyno Therapeutics | Dyno Therapeutics uses artificial intelligence to develop gene therapies. | Artificial intelligence | Series A | $100.0M | 2021-05-06 | $109.0M | Andreessen Horowitz, Google Ventures, CRV +2 | 101 to 250 | 2018 |
Table 1. Biotech startups in Cambridge, Massachusetts: the 25 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 272.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| 2 | Simnova | Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. | Biotech | Series B | $59.3M | 2026-08-18 | $87.2M | Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 | 51 to 100 | 2019 |
| 3 | Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| 4 | Atavistik Bio | Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. | Biotech | Series B | $40.0M | 2026-03-05 | $260.0M | Lux Capital, The Column Group, Nextech Invest | 11 to 50 | 2021 |
| 5 | Nocion Therapeutics | Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. | Biotech | Series B | $23.0M | 2026-01-07 | $134.0M | Canaan Partners, F-Prime, OUP (Osage University Partners) +2 | 11 to 50 | 2017 |
| 6 | Prudentia Sciences | Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. | Artificial intelligence | Series A | $20.0M | 2026-01-07 | $27.0M | Google Ventures, Iaso Ventures, Virtue | 1 to 10 | 2023 |
| 7 | STRM.BIO | STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy. | Biotech | Seed | $8.0M | 2026-01-07 | $10.1M | Bill & Melinda Gates Foundation, NYBC Ventures, NCATS | 11 to 50 | 2019 |
| 8 | Elemental Machines | Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. | Artificial intelligence | Series B | $5.7M | 2026-05-27 | $66.5M | Founders Fund, Tau Ventures, Rock Health Capital +2 | 11 to 50 | 2015 |
| 9 | NeuroBionics | NeuroBionics develops bioelectronic medicine devices that treat disease by modulating nerve activity. | Biotech | Seed | $4.2M | 2025-12-10 | $9.2M | MedTech Innovator, Dolby Family Ventures, GreyMatter +1 | 1 to 10 | 2023 |
| 10 | Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
Table 2. Biotech startups in Cambridge, Massachusetts: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | F-Prime | Venture capital firm | Cambridge, United States | 6 | 2% | 1 | Nocion Therapeutics |
| 2 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 5 | 2% | 1 | Kytopen |
| 3 | RA Capital Management | Startup incubator | Boston, United States | 5 | 2% | 1 | Terrestrial Bio |
| 4 | Y Combinator | Startup accelerator | Mountain View, United States | 4 | 1% | ||
| 5 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 4 | 1% | ||
| 6 | The Engine | Venture capital firm | Cambridge, United States | 3 | 1% | 2 | Kytopen, Terrestrial Bio |
| 7 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 3 | 1% | ||
| 8 | Google Ventures | Corporate venture arm | San Francisco, United States | 3 | 1% | 1 | Prudentia Sciences |
| 9 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 3 | 1% | 1 | Kytopen |
| 10 | MassVentures | Venture capital firm | Boston, United States | 3 | 1% | 2 | Kytopen, Stata DX |
| 11 | Deerfield | Hedge fund | New York, United States | 2 | 1% | ||
| 12 | Soma Capital | Venture capital firm | San Francisco, United States | 2 | 1% | ||
| 13 | Lux Capital | Venture capital firm | New York, United States | 2 | 1% | 1 | Atavistik Bio |
| 14 | Flagship Pioneering | Venture capital firm | Cambridge, United States | 2 | 1% | ||
| 15 | Casdin Capital | Venture capital firm | New York, United States | 2 | 1% |
Table 3. Biotech startups in Cambridge, Massachusetts: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 243 | 89% | $18.7B |
| Software | 45 | 17% | $2.4B |
| Artificial intelligence | 31 | 11% | $2.0B |
| Hardware | 6 | 2% | $406.0M |
| Fintech | 1 | 0% | $155K |
Table 4. Biotech startups in Cambridge, Massachusetts by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Cambridge, Massachusetts by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 3% | $15.0M |
| October 2026 | 1 | 3% | $150.0M |
| September 2026 | 4 | 11% | $62.3M |
| August 2026 | 4 | 11% | $256.0M |
| June 2026 | 5 | 13% | $270.5M |
| May 2026 | 2 | 5% | $127.7M |
| April 2026 | 3 | 8% | $101.6M |
| March 2026 | 7 | 18% | $313.1M |
| February 2026 | 1 | 3% | $400K |
| January 2026 | 8 | 21% | $234.5M |
| December 2025 | 2 | 5% | $4.4M |
Table 6. Biotech startups in Cambridge, Massachusetts: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 36 | 13% | $1.5B |
| 2025 | 31 | 11% | $1.7B |
| 2024 | 19 | 7% | $881.5M |
| 2023 | 27 | 10% | $1.7B |
| 2022 | 28 | 10% | $1.3B |
| 2021 | 25 | 9% | $1.6B |
Table 7. Biotech startups in Cambridge, Massachusetts by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 26 | 10% |
| 2020 to 2022 | 70 | 26% |
| 2015 to 2019 | 99 | 37% |
| 2010 to 2014 | 39 | 14% |
| Before 2010 | 36 | 13% |
Table 8. Biotech startups in Cambridge, Massachusetts by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 84 | 31% |
| 11 to 50 | 131 | 49% |
| 51 to 100 | 36 | 13% |
| 101 to 250 | 10 | 4% |
| 251 to 500 | 3 | 1% |
| 501 to 1,000 | 1 | 0% |
| 1,001 to 5,000 | 2 | 1% |
| 10,001 or more | 2 | 1% |
Table 9. Biotech startups in Cambridge, Massachusetts by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Cambridge, Massachusetts. On 16 November 2026 that is 272 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 25 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 272 rows: 26 have no round amount, 0 no city and 35 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Cambridge, Massachusetts are on the list?
- 272, in the file dated 16 November 2026. 38 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 272 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.